6505--Hydralazine Injection

The Department of Veterans Affairs National Acquisition Center is seeking a single contractor to supply Hydralazine Hydrochloride (HCL) Injections, specifically 20mg/mL, 1 mL vials, under Solicitation Number 36E79725R0048. The procurement is limited to U.S.-made pharmaceutical products and requires the contractor to supply VA facilities, Federal Health Care Centers, and Option 2 State Veteran Homes. Offerors must submit FDA-approved products manufactured in FDA cGMP-acceptable facilities, include bar codes, provide unique 11-digit National Drug Code (NDC) numbers, and incorporate a 0.5% Cost Recovery Fee in their pricing. The solicitation requires pricing submissions for both the base year and all four one-year option periods. Offers are due by August 25, 2025, at 2:30 PM CT, with contract award anticipated on or after July 24, 2025.

This procurement does not utilize any set-aside designations and will be distributed through the VA Pharmaceutical Prime Vendor program, which is currently operated by McKesson Corporation. The estimated annual usage requirement is 82,630 vials per year, structured as a base year contract with four one-year option periods for a total potential contract duration of five years. The contract structure suggests a substantial multi-year pharmaceutical supply agreement, though specific dollar values are not disclosed in the solicitation notice. Performance will involve nationwide distribution to various VA medical facilities and approved state veteran homes through the established prime vendor distribution network. The procurement falls under NAICS code 325412 for Pharmaceutical Preparation Manufacturing and PSC code 6505 for Drugs and Biologicals.